Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado / Response to ABVD chemotherapeutic protocol in patients with early stage Hodgkins lymphoma
Rev. méd. Chile
;
145(5): 619-622, mayo 2017. tab
Article
Dans Espagnol
| LILACS
| ID: biblio-1043141
ABSTRACT
Background:
Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported.Aim:
To report the experience in the treatment of ESHL. Material andMethods:
Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015.Results:
Twenty-two patients were treated. In 73%, the tumor was of nodular sclerosis histologic type. Most patients (95%) were in stage II, and 78% had a favorable prognosis according to the Deutsche Hodgkin Studiengruppe (GHSG) criteria. All patients were stratified using PET-CT and treated using the ABVD CT protocol, for 4-6 cycles. Only 5 patients received RT. There was no change of conduct after interim-PET-CT results. Ninety one percent of patients achieved complete response and there were two cases of refractory disease. Both cases underwent hematopoietic stem cell transplantation. After 17 months of median follow-up, 91% of patients are relapse-free, and only one patient died (5%).Conclusions:
ABVD offers excellent results for ESHL patients. The benefit of PET-CT should be evaluated with prospective protocols, aiming to select patients needing RT or to reduce the number of CT cycles.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Maladie de Hodgkin
/
Protocoles de polychimiothérapie antinéoplasique
Type d'étude:
Guide de pratique
/
Étude observationnelle
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Adulte
/
Femelle
/
Humains
/
Mâle
langue:
Espagnol
Texte intégral:
Rev. méd. Chile
Thème du journal:
Médicament
Année:
2017
Type:
Article
Pays d'affiliation:
Chili
Institution/Pays d'affiliation:
Pontificia Universidad Católica de Chile/CL
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS